The first experimental study on a candidate combined vaccine against hepatitis A and hepatitis E

Dong, Chen; Xing, Dan; Meng, Jingjing

doi:10.1016/j.vaccine.2006.11.001

Cited by 26 publications

(11 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chronic hepatitis E infection has also been documented in patients receiving immunosuppressive therapy following organ transplantation and those infected with HIV [15]. The immune responses to HEV involve antibody-mediated immunity, cell-mediated immunity, interferon and other host defenses [5,7,14,22]. Data from cellular immune responses to HEV suggest that the CD8 ?…”

Section: Discussionmentioning

confidence: 99%

Increased risk of hepatitis E virus infection in schizophrenia

Xue

Sun

et al. 2012

Arch Virol

Self Cite

View full text Add to dashboard Cite

Until now, the risk of HEV infection in schizophrenia was unknown. The present results showed that the seroprevalence of anti-HEV IgG and anti-HEV IgM in schizophrenia were significantly higher than that in healthy controls. Anti-HEV IgG positivity increased with age and with the duration of disease in schizophrenia patients. Moreover, schizophrenia patients with increased CD4(+)/CD8(+) T-cell ratios (>2.03) had higher anti-HEV IgG detection rates than those with normal ratios (1.05-2.03). Compared with the schizophrenia patients who tested anti-HEV IgG negative, the levels of interleukin-4 and interleukin-10 (Th2 cytokines) were significantly higher, while the interleukin-12 (Th1 cytokine) level was significantly lower, in those with anti-HEV IgG positivity. Of five schizophrenia patients who were anti-HEV IgM positive, four had elevated CD4(+)/CD8(+) T-cell ratios. HEV RNA was isolated from one of these four patients and classified as genotype 4. Anti-HEV IgM positivity was not detected among healthy controls. Therefore, schizophrenia patients exhibited a higher risk of HEV infection than controls.

show abstract

Section: Discussionmentioning

confidence: 99%

Increased risk of hepatitis E virus infection in schizophrenia

Xue

Sun

et al. 2012

Arch Virol

Self Cite

View full text Add to dashboard Cite

show abstract

“…The candidate hepatitis E vaccine, HEV p179, used in this study was expressed in E.coli -BL21(ED3)- pLysS strain (Novagen, Darmstadt, Germany) as described previously [18], [19]. It was produced by the Changchun Institute of Biological Products Co. Ltd, Chinese National Biotech Corporation (Changchun, China) in 10 µg/ml and 20 µg/ml formulated with alum adjuvant (1 mg/ml).…”

Section: Methodsmentioning

confidence: 99%

Rabbit as a Novel Animal Model for Hepatitis E Virus Infection and Vaccine Evaluation

et al. 2012

Self Cite

View full text Add to dashboard Cite

BackgroundThe identification of hepatitis E virus (HEV) from rabbits motivated us to assess the possibility of using rabbits as a non-human primate animal model for HEV infection and vaccine evaluation.Methodology/Principal FindingsFirst, 75 rabbits were inoculated with seven strains of genotypes 1, 3, 4, and rabbit HEV, to determine the appropriate strain, administrative route and viral dosage. Second, 15 rabbits were randomly divided into three groups and vaccinated with 0 µg (placebo), 10 µg and 20 µg of HEV candidate vaccine, HEV p179, respectively. After three doses of the vaccination, the rabbits were challenged with 3.3×105 genome equivalents of genotype 4 HEV strain H4-NJ703. The strain of genotype 1 HEV was not found to be infectious for rabbits. However, approximately 80% of the animals were infected by two rabbit HEV strains. All rabbits inoculated with a genotype 3 strain were seroconverted but did not show viremia or fecal viral shedding. Although two genotype 4 strains, H4-NJ153 and H4-NJ112, only resulted in part of rabbits infected, another strain of genotype 4, H4-NJ703, had an infection rate of 100% (five out of five) when administrated intravenously. However, only two out of fifteen rabbits showed virus excretion and seroconversion when inoculated orally with H4-NJ703 of three different dosages. In the vaccine evaluation study, rabbits vaccinated with 20 µg of the HEV p179 produced anti-HEV with titers of 1∶104–1∶105 and were completely protected from infection. Rabbits vaccinated with 10 µg produced anti-HEV with titers of 1∶103–1∶104 and were protected from hepatitis, but two out of the five rabbits showed virus shedding.Conclusions/SignificanceRabbits may be served as an alternative to the non-human primate models for HEV infection and vaccine evaluation when certain virus strains, appropriate viral dosages, and the intravenous route of inoculation are selected.

show abstract

“…Der Schwerpunkt der Entwicklung von Impfstoffen lag daher auf der DNA-Technologie oder auf rekombinanten Proteinen [59,60,61,62,63]. Einer der DNA-Impfstoffkandidaten ist zurzeit in der Phase II der klinischen Prüfung [63].…”

Section: Therapie Und Prophylaxeunclassified

Hepatitis-E-Virus

2008

Bundesgesundheitsbl.

View full text Add to dashboard Cite

The first experimental study on a candidate combined vaccine against hepatitis A and hepatitis E

Cited by 26 publications

References 24 publications

Increased risk of hepatitis E virus infection in schizophrenia

Increased risk of hepatitis E virus infection in schizophrenia

Rabbit as a Novel Animal Model for Hepatitis E Virus Infection and Vaccine Evaluation

Hepatitis-E-Virus

Contact Info

Product

Resources

About